
    
      The current clinical trial is a monocentric open phase1-2 trial in the context of rare
      diseases framework, aimed to the goal of defining the tolerance/efficacy of the treatment.

      Inclusion criteria: minimum age: 13 years Follow up in the Dept of Genetics, Hospital
      Necker-Enfants Malades, Paris, France
    
  